Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.44B

Market cap28.44B

Price-Earnings ratio

20.67

Price-Earnings ratio20.67

Dividend yield

—

Dividend yield—

Average volume

987.84K

Average volume987.84K

High today

—

High today—

Low today

—

Low today—

Open price

$197.25

Open price$197.25

Volume

0.00

Volume0.00

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $192.73. The company's market cap stands at 28.44B, with a P/E ratio of 20.67.

Biogen(BIIB) stock opened on 2026-06-09 at $197.25. The price climbed to — and dipped to —.

The Biogen(BIIB)'s current trading volume is 0, compared to an average daily volume of 987.84K.

During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.

BIIB News

MarketWatch 16h

Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch

...

Benzinga 21h

Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story

While Biogen Inc.'s (NASDAQ:BIIB) base business is declining, it is entering a period of pipeline optionality, with eight Phase III readouts through 2029, accor...

TipRanks 1d

Needham upgrades Biogen on pipeline potential, stabilizing core business

Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Biogen is entering a phase of eight Phase 3 readouts through 2029 amid an improved outl...

Analyst ratings

58%

of 38 ratings

Buy

57.9%

Hold

36.8%

Sell

5.3%

More BIIB News

TipRanks 1d

Biogen upgraded to Buy from Hold at Needham

Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking...

TipRanks 4d

Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

TipRanks 5d

UCB, Biogen announce dapirolizumab pegol data at EULAR

UCB and Biogen (BIIB) announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology, or EULAR, 2026 Cong...

Simply Wall St 5d

Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen

In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosu...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.